Inhibition of microRNA (miRNA)-21 could represent a therapeutic strategy for the treatment of chronic kidney diseases, including Alport nephropathy, say the researchers of a new study. Gomez et al. assessed the therapeutic potential of highly specific oligonucleotides that distribute to the kidney and inhibit miRNA function following subcutaneous administration. Injection of these oligonucleotides into mice with Alport nephropathy resulted in milder kidney disease, improved survival and reduced glomerulosclerosis, interstitial fibrosis and inflammation.